Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
J Surg Oncol. 2012 Dec;106(8):938-41. doi: 10.1002/jso.23203. Epub 2012 Jun 27.
The aim of this study was to analyze the stage migration and survival of endometrial cancer by the revised FIGO 2008 staging system compared with the 1988 staging system.
A total of 355 patients with endometrial cancer, who underwent complete surgical staging, were enrolled. We compared the surgical stages and survival by FIGO 1988 staging system with those by FIGO 2008 staging system.
2008 FIGO staging system resulted in an increase of stage I patients and decrease of stage II and IIIa patients. The 5-year overall survival (OS) rates for patients with 2008 FIGO stage IA and IB disease were 98.2% and 91.9%, respectively (P = 0.004). Five-year OS rate of new stage II (82.6%) was significantly worse than that of new stage IA (98.2%, P = 0.003). Patients with positive washing cytology alone revealed a 5-year OS rate similar to that of patients with new stage IIIA disease (96.2% vs. 90.9%, respectively; P = 0.53). The 5-year OS rate for patients with stage IIIC1 disease was improved compared with that for patients with stage IIIC2 disease (85.7% vs. 63.0%, respectively; P = 0.08).
New revised FIGO 2008 staging system for endometrial cancer produced better discrimination in OS outcomes compared with the 1988 system.
本研究旨在通过修订后的 2008 年 FIGO 分期系统与 1988 年分期系统比较，分析子宫内膜癌的分期迁移和生存情况。
共纳入 355 例接受完全手术分期的子宫内膜癌患者。我们比较了 FIGO 1988 分期系统和 FIGO 2008 分期系统的手术分期和生存情况。
2008 年 FIGO 分期系统导致Ⅰ期患者增加，Ⅱ期和Ⅲa 期患者减少。2008 年 FIGO 分期 IA 和 IB 期患者的 5 年总生存率（OS）分别为 98.2%和 91.9%（P=0.004）。新的Ⅱ期（82.6%）5 年 OS 率明显低于新的Ⅰ期（98.2%，P=0.003）。单纯阳性冲洗细胞学的患者 5 年 OS 率与新的ⅢA 期患者相似（分别为 96.2%和 90.9%；P=0.53）。与ⅡIC2 期患者相比，ⅡIC1 期患者的 5 年 OS 率有所提高（分别为 85.7%和 63.0%；P=0.08）。
与 1988 年系统相比，新修订的 2008 年 FIGO 子宫内膜癌分期系统在 OS 结果方面具有更好的区分度。
